Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-12-30: Form 8-K; Period of report 2022-12-28; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2022-11-14: Form 8-K; Period of report 2022-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-08-25: Form 8-K; Period of report 2022-08-24; Description 8.01 Other Events; Details 8.01.
- 2022-08-09: Form 8-K; Period of report 2022-08-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-12-30 | 8-K | 2022-12-28 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 28, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). | brhc10046105_8k.htm |
| 2022-11-14 | 8-K | 2022-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended September 30, 2022 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20221114.htm |
| 2022-08-25 | 8-K | 2022-08-24 | 8.01 Other Events | 8.01 As previously disclosed in the Current Report on Form 8-K of Infinity Pharmaceuticals, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “Commission”) on May 24, 2022, the Company received a notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, for the prior thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). | brhc10041208_8k.htm |
| 2022-08-09 | 8-K | 2022-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended June 30, 2022 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20220809.htm |
| 2022-06-16 | 8-K | 2022-06-16 | 5.07 Submission of Matters to a Vote of Security Holders | brhc10038855_8k.htm | |
| 2022-05-24 | 8-K | 2022-05-24 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 24, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). | brhc10038060_8k.htm |
| 2022-05-03 | 8-K | 2022-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended March 31, 2022 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20220503.htm |
| 2022-03-29 | 8-K | 2022-03-25 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On March 29, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the year ended December 31, 2021 and will conduct a previously announced, publicly available conference call to discuss those results. 5.02 (d) On March 25, 2022, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from seven to eight members and appointed Mr. Sujay Kango as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”). | infi-20220325.htm |
| 2022-01-05 | 8-K | 2022-01-05 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2021, on January 5, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) announced that it expects to report that it had approximately $81 million in cash and investments (unaudited) as of December 31, 2021. 8.01 On January 5, 2022, the Company issued a press release announcing its 2022 business goals and financial guidance and providing an update regarding its clinical development strategy. | infi-20220105.htm |